1-(4-methoxycarbonylphenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-2-ium-3-carboxylate

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 英文名称: 1-(4-methoxycarbonylphenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-2-ium-3-carboxylate
• 化学式: C₂₀H₁₈N₂O₄
• 分子量: 350.374
• InChiKey: LGZGOHXTBJSWFV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  91.4
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(4-methoxycarbonylphenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-2-ium-3-carboxylate 在 碘苯二乙酸 、 硫酸 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 39.0h， 生成
  参考文献：
  名称：

  [EN] SMALL MOLECULE INHIBITORS OF THE CRL4 UBIQUITIN LIGASE
  [FR] INHIBITEURS À PETITES MOLÉCULES DE L'UBIQUITINE LIGASE CRL4

  摘要：

  Compounds of formula (I), compounds of formula (II), and compounds of formula (III) are disclosed. Also disclosed are compounds, compositions, and methods to inhibit CUL4A expression or activity, CUL4B expression or activity, and/or DDB1 expression or activity for the treatment or prevention of cancer, DNA damage, or related conditions. In some aspects, the interaction between CUL4A and/or CUL4B and the beta-propeller B of DDB1 is disrupted with the compounds, compositions, or methods.

  公开号：

  WO2023173136A2
• 作为产物：
  描述：

  DL-色氨酸 、 对甲酰基苯甲酸甲酯 在 溶剂黄146 作用下， 生成 1-(4-methoxycarbonylphenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-2-ium-3-carboxylate
  参考文献：
  名称：

  [EN] SMALL MOLECULE INHIBITORS OF THE CRL4 UBIQUITIN LIGASE
  [FR] INHIBITEURS À PETITES MOLÉCULES DE L'UBIQUITINE LIGASE CRL4

  摘要：

  Compounds of formula (I), compounds of formula (II), and compounds of formula (III) are disclosed. Also disclosed are compounds, compositions, and methods to inhibit CUL4A expression or activity, CUL4B expression or activity, and/or DDB1 expression or activity for the treatment or prevention of cancer, DNA damage, or related conditions. In some aspects, the interaction between CUL4A and/or CUL4B and the beta-propeller B of DDB1 is disrupted with the compounds, compositions, or methods.

  公开号：

  WO2023173136A2

文献信息

• Tetracyclic derivatives, process of preparation and use
  申请人：ICOS Corporation

  公开号：US20020119976A1

  公开（公告）日：2002-08-29

  A compound of formula (I) 1 and salts and solvates thereof, in which: R o represents hydrogen, halogen or C 1-6 alkyl; R 1 represents hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halo C 1-6 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl C 1-3 alkyl, arylC 1-3 alkyl or heteroaryl C 1-3 alkyl; R 2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring 2 attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R 3 represents hydrogen or C 1-3 alkyl, or R 1 and R 3 together represent a 3- or 4-membered alkyl or alkenyl chain. A compound of formula (I) is a potent and'selective inhibitor of cyclic guanosine 3′, 5′-monophosphate specific phosphodiesterase (CGMP specific PDE) having a utility in a variety of therapeutic areas where such inhibition is beneficial, including the treatment of cardiovascular disorders.

  式(I)1的化合物及其盐和溶剂化物，其中：R代表氢，卤素或C1-6烷基；R1代表氢，C1-6烷基，C2-6烯基，C2-6炔基，卤代C1-6烷基，C3-8环烷基，C3-8环烷基C1-3烷基，芳基C1-3烷基或杂环芳基C1-3烷基；R2代表一个可选的取代的单环芳香环，选择自苯，噻吩，呋喃和吡啶或一个可选的取代的二环2，通过苯环碳原子之一连接到分子的其余部分，其中融合的环A是一个5-或6-成员环，可以是饱和的或部分或完全不饱和的，并包括碳原子和可选的一个或两个异原子，选择自氧，硫和氮；R3代表氢或C1-3烷基，或R1和R3一起代表一个3-或4-成员烷基或烯基链。式(I)的化合物是环鸟苷3'，5'-单磷酸特异性磷酸二酯酶（CGMP特异性PDE）的有效和选择性抑制剂，具有在多种治疗领域中抑制有益的功效，包括心血管疾病的治疗。
• Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B] indole derivatives
  申请人：——

  公开号：US20020035111A1

  公开（公告）日：2002-03-21

  A method for inhibiting neoplasia, particularly cancerous and precancerous lesions by exposing the affected cells to pyrido[3,4b]indoles.

  一种通过将受影响的细胞暴露于吡啶并［3,4b］吲哚来抑制肿瘤，特别是癌症和癌前病变的方法。
• (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione for the treatment of benign prostatic hypertrophy
  申请人：ICOS Corporation

  公开号：EP2036560A1

  公开（公告）日：2009-03-18

  Compound (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino [2', 1':6,1]pyrido[3,4-b]indcle-1,4-dione for the treatment of benign prostatic hypertrophy.

  用于治疗良性前列腺肥大的化合物 (6R,12aR)-2,3,6,7,12,12a-六氢-2-甲基-6-(3,4-亚甲基二氧苯基)-吡嗪并[2', 1':6,1]pyrido[3,4-b]indcle-1,4- 二酮。
• Tetracyclic cyclic gmp-specific phosphodiesterase inhibitors for the treatment of benign prostatic hypertrophy
  申请人：ICOS Corporation

  公开号：EP2327408A1

  公开（公告）日：2011-06-01

  A compound of formula (1) and salts and solvates thereof, in which: R0 represents hydrogen, halogen, or Cl-6alkyl; R1 represents hydrogen, C1-6-alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C3-8cycloalkyl, C3-8cyloalkylcl-3alkyl, arylC1-3alkyl, or heteroarylcl-3alkyl; R2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan, and pyridine, or an optionally substituted bicyclic ring (a) attached to the rest of the molecule via one of the benzene ring carbon atoms, and wherein the fused ring (A) is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated, and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur, and nitrogen; and R3 represents hydrogen or Cl-alkyl, or R1 and R3 together represent a 3- or 4-membered alkyl or alkenyl chain. A compound of formula (I) is a potent and selective inhibitor of cyclic guanosine 3', 5'-monophosphate specific phosphodiesterase (cGMP specific PDE) having a utility in a variety of therapeutic areas where such inhibition is beneficial, including the treatment of benign prostatic hypertrophy.

  式(1)化合物及其盐和溶剂，其中：R0 代表氢、卤素或 Cl-6 烷基；R1 代表氢、C1-6-烷基、C2-6-烯基、C2-6-炔基、卤代 C1-6 烷基、C3-8-环烷基、C3-8-环烷基环 3 烷基、芳基 C1-3 烷基或杂芳基环 3 烷基；R2 代表任选取代的单环芳香环，选自苯、噻吩、呋喃和吡啶，或任选取代的双环 (a)，通过其中一个苯环碳原子连接到分子的其余部分，其中融合环 (A) 是 5 或 6 元环，可以是饱和环或部分或完全不饱和环，包括碳原子和任选选自氧、硫和氮的一个或两个杂原子；R3 代表氢或 Cl-烷基，或 R1 和 R3 共同代表 3 或 4 元烷基或烯基链。式（I）化合物是环鸟苷-3'，5'-单磷酸特异性磷酸二酯酶（cGMP 特异性 PDE）的强效选择性抑制剂，可用于多种治疗领域，包括治疗良性前列腺肥大。
• TETRACYCLIC DERIVATIVES, PROCESS OF PREPARATION AND USE
  申请人：ICOS CORPORATION

  公开号：EP0740668B1

  公开（公告）日：1998-07-29